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BACKGROUND. Bacterial vaginosis (BV) causes genital inflammation and increases HIV risk, whereas a vaginal microbiota
dominated by Lactobacillus species is associated with immune quiescence and relative HIV protection. BV treatment reduces
genital inflammation, but it is unclear whether this reduction is driven by a decrease in BV-associated bacteria or an increase
in Lactobacillus species.
METHODS. To evaluate the short-term effect of standard BV treatment on genital immunology and the vaginal microbiota,
vaginal swabs were collected immediately before and after metronidazole treatment for BV and analyzed with multiplex
ELISA, metagenomic sequencing, and quantitative PCR.
RESULTS. Topical metronidazole treatment rapidly reduced vaginal levels of proinflammatory cytokines, chemokines,
and soluble immune markers of epithelial barrier disruption. Although the vaginal microbiota shifted to dominance by
L. iners or L. jensenii, this proportional shift was primarily driven by a 2 to 4 log10–fold reduction in BV-associated bacteria
absolute abundance. BV treatment induced no change in the absolute abundance of L. crispatus or L. iners and only minor
(<1 log10–fold) increases in L. gasseri and L. jensenii that were not independently associated with reduced inflammation in
multivariable models.
CONCLUSION. The genital immune benefits that are associated with Lactobacillus dominance after BV treatment were not
directly attributable to an absolute increase in lactobacilli, but rather to the loss of BV-associated bacteria.
TRIAL REGISTRATION. Participants were recruited as part of a randomized controlled trial (ClinicalTrials.gov NCT02766023)
from 2016 to 2019.
FUNDING. Canadian Institutes of Health Research (PJT-156123) and the National Institute of Allergy and Infectious Diseases
(HHSN2722013000141 and HHSN27200007).

Introduction

The vaginal microbiota is an important determinant of HIV transmission and acquisition risk among women (1). In general, the
vaginal microbiota is either dominated by one of several species of
Lactobacillus or is composed of a diverse community of anaerobic
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bacteria, which are defined as bacterial vaginosis (BV; refs. 2, 3).
Although BV is often asymptomatic, it consistently induces genital proinflammatory cytokines, such as IL-1α (1, 4), which in turn
increase HIV risk by recruiting activated CD4+ T cells to the vaginal mucosa and by directly disrupting the genital epithelial barrier
(5, 6). In contrast, vaginal microbiome predominance by Lactobacillus species, in particular by the species L. crispatus, L. jensenii,
or L. gasseri, has been associated with relative mucosal immune
quiescence and protection against HIV acquisition (1).
Historically, diagnosis of BV and characterization of the vaginal microbiota relied on the presence of symptoms or the calculation of a Nugent score from a vaginal Gram stain (7, 8), but
1
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treatment (15); treatment also reduced vaginal proinflammatory cytokines but unexpectedly increased vaginal chemoattractant
chemokines, such as IP-10 (15). However, it
was unclear whether these immune changes were driven by a reduced abundance of
BV-associated bacteria or by an increase
in Lactobacillus abundance. Furthermore,
immune changes seen several weeks after
treatment could have been driven by antibiotic-mediated reductions in some vaginal
bacteria, posttreatment reexpansion of others, or a combination of both.
Since the maximal impact of standard
BV treatment on the vaginal microbiota is
seen immediately after treatment (16), we
hypothesized that the greatest alterations
in genital immunology would occur at a
similar time. Therefore, to better characterize the interaction of microbiota change
with host immunology after BV treatment,
we characterized longitudinal changes in
genital immunology, vaginal microbiota
community composition, and the absolute
abundance of key vaginal bacteria before
and immediately after metronidazole
Figure 1. Flow chart of study design. This flow diagram was adapted from the original clinical trial by
treatment. We demonstrated that standard
Cohen et al. (17) and expanded to include the selection criteria and sample size for this substudy.
metronidazole treatment rapidly and dramatically reduced vaginal levels of proinflammatory cytokines, chemokines, and
immune factors linked to epithelial barrier disruption. Although
advancements in molecular technologies now make it possible
genital immune changes were accompanied by a shift in the vagto characterize the vaginal microbiota with greater taxonomic
inal microbiota toward Lactobacillus predominance, immune
resolution and accuracy. Molecular methods have expanded our
changes were driven by a large decrease in the absolute abununderstanding of the vaginal microbiota and allow for classificadance of BV-associated bacteria, rather than by any increase in
tion into discrete community state types (CSTs) that are characterabsolute Lactobacillus abundance.
ized either by the dominance of BV-associated bacteria or by one
of several Lactobacillus species. Methods used to characterize the
vaginal microbiota generally employ 16S rRNA gene sequencing
Results
or metagenomic sequencing, which generate the relative abunParticipant characteristics. This study enrolled a subset of 48 pardance of all bacteria or all genes (including those from nonbacteticipants from the LACTIN-V clinical trial (ClinicalTrials.gov
rial species) in a sample, respectively (2, 9). However, while these
NCT02766023) investigating the impact of an L. crispatus–based
technologies allow researchers to investigate the presence of both
live biotherapeutic on BV recurrence after a standard 5-day course
known and novel gene transcripts in a sample, they are unable to
of topical metronidazole (17); these participants were randomly
determine the absolute number of gene targets (10, 11). In conselected from those who attended all clinic visits during the clintrast, quantitative PCR (qPCR) allows for the determination of
ical trial (Figure 1). All samples were collected before administhe absolute number of gene targets in a sample but can only be
tration of LACTIN-V or a placebo. Participant sociodemographic
performed for a restricted number of gene targets (12). Although
characteristics are presented in Table 1. The average age of partic16S rRNA gene sequencing and metagenomic sequencing tend to
ipants was 31.5 years; most participants identified as either White
be the preferred method of characterizing the overall community
(41.7%) or Black (41.7%), with a minority of participants identifycomposition of the vaginal microbiota, there is emerging evidence
ing as Asian (6.3%), multiracial (2.1%), or unknown (8.3%). The
that relative abundance data alone may not predict longitudinal
majority of participants reported no intravaginal practices, includchanges in the absolute abundance of key vaginal bacteria (13).
ing douching, within 30 days of the baseline visit or between the
Given the strong association of BV with HIV transmission risk,
baseline and follow-up. Although most participants reported vagBV-focused clinical interventions may reduce HIV transmission
inal sex within 30 days of the baseline visit (79.2%), few reported
(14). Previous work in Kenyan women found that successful BV
vaginal sex between baseline and the posttreatment visit (27.1%).
treatment reduced the relative abundance of BV-associated bacMost participants (77.1%) reported no hormonal contraceptive use
teria and increased the relative abundance of L. iners 1 month after
at baseline (Table 1).
2
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Table 1. Participant sociobehavioral characteristics
Characteristic
Age
Race
Asian
Black or African American
Multiracial
White
Unstated
Intravaginal practices within 30 days of baseline
Intravaginal practices between baseline and
follow-up
Sex within 30 days of baseline
Sex between baseline and follow-up
Contraceptive use
Injectable
Oral contraceptive
Implant
Hormonal IUD
Contraceptive patch
None

Median (range) or frequency (%)
31.5 (19–48)
3 (6.3)
20 (41.7)
1 (2.1)
20 (41.7)
4 (8.3)
0 (0–1)
1 (2.1)
38 (79.2)
13 (27.1)
1 (2.1)
4 (8.3)
1 (2.1)
4 (8.3)
1 (2.1)
37 (77.1)

Impact of metronidazole treatment on vaginal soluble immune
factors. We first assessed the impact of topical metronidazole
treatment on log10-transformed genital levels of cytokines and
other soluble immune factors, including IL-1α, IFN-α2a, IL-17A,
IL-6, IP-10, IL-8, macrophage inflammatory protein 1β (MIP-1β),
MIP-3α, monokine-induced by IFN-γ (MIG), soluble E-cadherin, and MMP-9. Most soluble immune factors were detectable
in over 50% of samples except IFN-α2a and IL17-A, which were
dichotomized and reported as detectable or undetectable. Metronidazole treatment induced a rapid and substantial decrease
in multiple inflammatory markers, including IL-1α (3.0-fold, P <
0.0001), IL-6 (8.6-fold, P < 0.0001), IL-8 (6.7-fold, P < 0.0001),
MIP-1β (3.5-fold, P = 0.0011), MIP-3α (2.8-fold, P = 0.0001), soluble E-cadherin (12.3-fold, P < 0.0001), and MMP-9 (40.9-fold, P <
0.0001; Figure 2) and a drop in the frequency of IL-17A detection
(58.3% vs. 22.9%; P = 0.0005; Figure 3). There was no association
of baseline immune parameters before metronidazole treatment
and sex within 30 days of baseline visit (Supplemental Tables 1
and 2; supplemental material available online with this article;
https://doi.org/10.1172/JCI152930DS1), hormonal contraceptive
use (Supplemental Tables 3 and 4), or type of hormonal contraception (Supplemental Tables 5 and 6).
CST transitions after metronidazole treatment. Metagenomic
data were available for 45 participants (94%) prior to treatment
and for 32 participants (81%) after metronidazole treatment. Prior to treatment, all participants’ vaginal CSTs were either characterized by diverse BV-associated bacteria (CST-IV; 40/45, 89%)
or L. iners (CST-III; 5/45, 11%) (Figure 4A). Vaginal CSTs were
very different immediately after metronidazole treatment, when
most participants had CST-III (14/32, 49%) or a CST dominated
by L. jensenii (CST-V; 11/32, 31%); the remainder had either CSTIV (5/32, 10%) or a CST dominated by L. gasseri (CST-II; 2/32,
10%) (Figure 4B). Paired comparisons of the relative abundance

of key bacterial taxa were consistent with these findings; metronidazole treatment induced an overall decrease in the relative
abundance of the BV-associated bacteria Gardnerella vaginalis
(P = 0.003), Prevotella species, Atopobium vaginae, and Megasphaera species (all P < 0.001) and an overall increase in the relative abundance of L. crispatus, L. iners, L. jensenii (all P < 0.001),
and L. gasseri (P = 0.005) (Figure 5).
Change in the absolute abundance of key bacteria after metronidazole treatment. Although an increase in the relative abundance
of an organism can represent an increase in the absolute abundance of the organism of interest, it may also represent a decrease
in the absolute abundance of other organisms in the sample while
the absolute abundance of the organism of interest remains
unchanged. Therefore, we evaluated the impact of metronidazole treatment on the absolute abundance of the BV-associated
bacteria G. vaginalis, Prevotella spp., A. vaginae, and Megasphaera
spp. and L. crispatus, L. iners, L. jensenii, and L. gasseri by measuring log10-transformed copy numbers of each taxon with targeted
qPCR. The absolute abundances of each taxon for each CST are
displayed in Supplemental Figure 1. This approach demonstrated
that metronidazole treatment induced dramatic reductions in the
copy numbers of the BV-associated taxa G. vaginalis (2.2-fold),
Prevotella spp. (3.8-fold), A. vaginae (3.6-fold), and Megasphaera
spp. (3.3-fold; all P < 0.001). However, treatment induced no
change in copy numbers of L. iners (0.2-fold reduction; P = 0.245)
or L. crispatus (0.2-fold increase; P = 0.563), and while there was
a significant increase in the copy numbers of L. jensenii (0.9-fold;
P = 0.006) and L. gasseri (0.7-fold; P = 0.006), the magnitude of
this change was much less than the decrease in BV-associated
bacteria (Figure 6). Lactobacillus spp., G. vaginalis, A. vaginae, and
Megasphaera were quantified using multiplex assays. To rule out
any impact of the multiplex format on bacterial quantification,
we repeated qPCR assays for L. crispatus, L. iners, and G. vaginalis in single-plex with standard curves and generated very similar
results (Supplemental Table 7).
Associations between immune factors and bacterial abundance.
To further explore associations between changes in the absolute
abundance of key bacteria taxa and soluble immune factors, we
generated a linear mixed model that included the absolute abundances of key vaginal bacteria taxa to predict levels or detectability of soluble immune factors. Participant ID was included in the
model as a random effect to allow for the inclusion of correlated
observations at both baseline and follow-up without violating the
assumption of independence. To account for multicollinearity
between BV-associated taxa, the absolute abundance of all BVassociated bacteria (G. vaginalis, A. vaginae, Prevotella spp., and
Megasphaera spp.) were combined into a single composite variable
(Table 2). Given that many tests were performed, a more stringent
P value of 0.01 was used as the significance cutoff. BV-associated bacteria were significantly associated with elevated IL-1α (P
< 0.001), IL-6 (P < 0.01), soluble E-cadherin (P < 1 × 10–10), and
MMP-9 (P < 0.0001). None of the Lactobacillus species’ absolute
abundances were significantly associated with any of the soluble
immune factors. To ensure that combining the absolute abundances of BV-associated bacteria into a single composite variable
did not skew the results in favor of detecting immune associations,
we repeated the analysis with non–iners Lactobacillus species com-
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Figure 2. Rapid impact of topical
metronidazole on vaginal immunology and markers of epithelial
barrier disruption. Log10-transformed vaginal levels of (A) IL-1α, (B)
IL-6, (C) IL-8, (D) IP-10, (E) MIP-1β,
(F) MIP-3α, (G) soluble E-cadherin, (H) MIG, and (I) MMP-9 were
compared before and immediately
after metronidazole treatment,
using Wilcoxon’s matched-pairs
signed-rank test (n = 48). P values
are reported above graph.

bined into a single composite variable and observed similar results
(Supplemental Table 8). The linear mixed model analysis results
also remained similar after including hormonal contraception as
an independent variable (Supplemental Table 9).

Discussion

A better understanding of how standard BV treatment affects
genital immunology is required to develop an HIV prevention
strategy that optimizes the vaginal microbiome. Here, we showed
that standard BV treatment with topical metronidazole resulted
in a rapid and dramatic reduction in proinflammatory cytokines,
chemokines, and immune factors linked to epithelial barrier disruption, without an increase in chemokines linked to HIV acquisition. Although these immune changes were accompanied by
an overall shift in the vaginal microbiota to Lactobacillus dominance, this dominance shift was driven by an absolute reduction
in BV-associated bacteria rather than an increase in Lactobacillus
spp. These findings have important clinical implications for the
potential inclusion of BV treatment in HIV prevention strategies
and highlight limitations of relative abundance data when interpreting clinical and/or immune changes induced by microbiomefocused clinical interventions.
A previous study demonstrated that BV clearance 1 month
after standard antibiotic treatment resulted in a reduction in vaginal proinflammatory cytokine levels while unexpectedly increasing levels of vaginal chemokines linked to HIV risk (15). The cur4

rent study focused on the immediate impact of metronidazole
treatment and found that within 48 hours of treatment completion
there was a dramatic reduction in vaginal levels of proinflammatory cytokines (IL-1α, IL-6), chemokines (IL-8, MIP-1β, MIP-3α),
and immune factors linked to epithelial barrier disruption (soluble E-cadherin, MMP-9). Among these immune factors, IL-1α,
IL-8, and MIP-1β have been directly linked to elevated HIV risk
among women (18). E-cadherin is a key component of adherens
junctions between epithelial cells, and its soluble form, soluble
E-cadherin, has been recognized as biomarker for impaired epithelial barrier integrity in various anatomical sites in vivo (19) and
has been linked to cervical epithelial barrier disruption in vitro
(20, 21). To our knowledge, this is the first study that has utilized
soluble E-cadherin as an in vivo biomarker of epithelial barrier
disruption in the female genital tract and linked it to BV-associated bacteria. Similarly, MMP-9 is produced by neutrophils and can
contribute to epithelial disruption by directly cleaving E-cadherin
(22). In contrast to the 1-month posttreatment study (15), we did
not observe any increase in the chemokines IP-10 or MIG after BV
treatment. Since there were only minor increases in L. jensenii and
L. gasseri abundance after treatment and no change in L. iners or
L. crispatus, our results suggest that changes in Lactobacillus spp.
abundance may drive vaginal levels of the chemokines IP-10 and
MIG and that the chemokine increases seen several weeks after
treatment (15) may represent subsequent lactobacillus expansion.
Collectively, these findings suggest that the abundance of BV-
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Figure 3. Rapid impact of topical metronidazole on detectability of vaginal soluble immune factors. Detectability of (A) IFN-α2a and (B) IL-17A
was compared before and immediately after metronidazole treatment
using McNemar’s test (n = 48). P values are reported above each graph.

associated bacteria is a key determinant of genital inflammation
and epithelial barrier disruption but is not contributing to vaginal
levels of the proinflammatory chemokines IP-10 and MIG.
Our findings also suggest that relative abundance data may be
a poor predictor of biologically, immunologically, or clinically relevant longitudinal changes in the abundance of key vaginal bacteria. Culture-independent molecular methods, such as 16S rRNA
gene sequencing and shotgun metagenomic sequencing, have
become the preferred method of characterizing the vaginal microbiota because they allow researchers to characterize entire vaginal
bacterial communities by generating relative abundance data for
all bacteria present in the vaginal microbiota. However, Tettamanti Boshier and colleagues recently incorporated both 16S rRNA

gene sequencing and targeted qPCR to characterize the vaginal
microbiota. They demonstrated that longitudinal change in the
relative abundance of multiple vaginal bacteria weakly predicted
change in absolute abundance, suggesting that relative abundance
data may not accurately reflect changes in the absolute abundance
of vaginal bacteria (13). By complementing metagenomic data
with targeted qPCR, we showed that distinct associations can be
observed when analyzing the relative and absolute abundance of
vaginal bacteria. Consistent with other work, we found that standard BV treatment resulted in overall shifts in the vaginal microbiota toward Lactobacillus dominance (15). Unsurprisingly, these
shifts were due to overall reductions in the relative abundance of
BV-associated bacteria and an increase in the relative abundance

Figure 4. Shift of the vaginal microbiome to
Lactobacillus spp. predominance after metronidazole treatment of BV. (A) The stacked
bar plot shows the relative abundances of the
most common vaginal bacterial taxa among
participants with clinical BV prior to treatment,
organized by community state type (CST; n =
45). (B) The stacked bar plot shows the relative
abundances of the most common bacterial taxa
immediately after metronidazole treatment,
organized by CST (n = 32).
J Clin Invest. 2022;132(6):e152930 https://doi.org/10.1172/JCI152930
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Figure 5. Impact of metronidazole treatment on the relative
abundance of BV-associated bacteria and vaginal Lactobacillus species. Forest plot showing the impact of metronidazole
treatment on the relative abundance of L. crispatus, L. iners,
L. gasseri, and L. jensenii and the BV-associated bacteria
Prevotella, G. vaginalis, A. vaginae, and Megasphaera (n = 32).
Boxes represent the mean percentage change and whiskers represent the 95% CI. P values were determined with Wilcoxon’s
matched-pairs signed-rank test.

of Lactobacillus spp., especially L. iners. However, after measuring the absolute abundance of key vaginal bacteria, we demonstrated that treatment resulted in a substantial reduction in the
absolute abundance of BV-associated bacteria and much smaller
or no change in the absolute abundance of Lactobacillus spp. Similarly, Srinivasan and colleagues demonstrated a rapid reduction
in the absolute abundance of BV-associated bacteria immediately
after standard BV treatment (23). Although molecular techniques
such as metagenomic sequencing and 16S rRNA sequencing offer
researchers the ability to characterize the entire vaginal microbiota and discover novel taxa, our findings suggest that relative abundance data is a poor predictor of temporal changes in the absolute
abundance of key vaginal bacteria taxa. We believe these findings
have significant implications for other studies investigating longitudinal changes in the vaginal microbiota and make a strong
case for the supplementation of relative abundance methods with
absolute abundance methods in this context.
There are some limitations to our study. First, adherence to
metronidazole was self-reported by study participants, leaving
the possibility of overreporting of adherence due to desirability
bias and limiting our ability to definitively conclude that all the
observed immune and microbial changes were caused by metronidazole treatment. However, the high clearance rate of molecu-

lar BV after treatment was consistent with initial success rates of
metronidazole treatment and gives us confidence that treatment
adherence was high. Menstrual cycle stage was not recorded, but
all participants were enrolled shortly after the end of menstruation to ensure that initial topical metronidazole administration
and collection of genital samples did not occur during menses.
Third, the strong correlation between the change in the absolute
abundance of different BV-associated taxa after treatment limited our ability to identify whether specific taxa were disproportionately responsible for changes in soluble immune factors. Also,
the lack of change in the absolute abundance of Lactobacillus spp.
limited our ability to identify the genital immune impact associated with these species. Future studies should elucidate the role of
individual BV-associated taxa in driving genital inflammation and
the genital immune impact of increasing Lactobacillus absolute
abundance in vivo using approaches to supplement vaginal lactobacilli. Analysis of immune and microbial shifts at additional time
points after BV treatment would also be very interesting but was
not feasible in the current analysis because of subsequent participant administration of a live biotherapeutic.
Our study demonstrated that metronidazole-induced reductions in BV-associated bacteria rapidly reversed mucosal immune
changes that enhance HIV risk in women with BV, including ele-

Figure 6. Impact of metronidazole treatment on the absolute
abundance of BV-associated bacteria and vaginal Lactobacillus
species. Forest plot shows change in absolute abundance of
L. crispatus, L. iners, L. gasseri, and L. jensenii and the BV-associated bacteria Prevotella, G. vaginalis, A. vaginae, and Megasphaera, represented by log10-transformed fold change (n = 48).
Boxes represent the mean log10-transformed fold change and
whiskers represent the 95% CI. P values were determined with
Wilcoxon’s matched-pairs signed-rank test.
6
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Table 2. Multivariable modeling of the associations between vaginal immune parameters and the absolute abundances of key vaginal
bacteria

BV taxa
L. iners
L. crispatus
L. gasseri
L. jensenii

Fixed effect estimates
IP-10
MIP-1β

IFN-α2a

IL-17A

IL-1α

IL-6

IL-8

–0.001
0.033
0.008
–0.005
–0.038

0.009
0.037
–0.025
–0.018
0.011

0.025A
0.055
–0.005
–0.016
0.029

0.026B
0.023
0.017
–0.052
–0.042

0.025
0.012
–0.001
–0.038
–0.001

–0.003
0.056
0.017
0.013
–0.046

0.007
0.028
–0.013
–0.031
–0.001

MIP-3α

Soluble
E-cadherin

MIG

MMP-9

0.014
–0.009
0.006
–0.058
–0.012

0.057C
–0.019
–0.008
–0.014
–0.005

–0.009
0.103
0.025
–0.057
–0.015

0.071D
–0.045
–0.005
–0.094
0.022

Linear mixed model analysis. Numerical values represent the fixed effect estimates. P values of 0.01 were deemed significant. AP < 0.001, BP < 0.01, CP < 1 ×
10–10, DP < 0.0001.

vated vaginal proinflammatory cytokines and markers of epithelial barrier disruption, in the absence of substantial changes in
Lactobacillus spp. absolute abundance. While strategies to supplement vaginal lactobacilli, particularly L. crispatus, may reduce
the subsequent posttreatment expansion of BV-associated bacteria, these benefits must be balanced against potential lactobacillus-associated increases in vaginal chemokines, such as IP-10
and MIG. In addition, our findings underscore the importance of
employing molecular methods that generate absolute as well as
relative abundance data to characterize the vaginal microbiota,
especially when studying the clinical or immune effects of longitudinal microbiota changes.

Methods

Study participants. Participants were recruited as part of a phase 2b
randomized, placebo-controlled clinical trial of a Lactobacillus crispatus-based live biotherapeutic (LACTIN-V) to prevent BV recurrence
after standard antibiotic treatment. Out of 228 women who were
enrolled in the larger clinical trial, a subset of 48 women who attended
all clinic visits were selected for the current substudy. At baseline, participants’ medical history was obtained, and physical and pelvic examinations were performed. Potentially eligible participants had a vaginal swab obtained for Gram staining to determine the Nugent score if
at least 3 of 4 Amsel criteria were met. A Nugent score of 4 to 10 at the
baseline visit had to be met for eligibility. Blood was collected for HIV
and syphilis diagnostics and a vaginal swab was obtained for gonorrhea, chlamydia, and trichomonas diagnostics. Urine was also collected for human chorionic gonadotropin and urinalysis. All potentially
eligible participants who had negative tests for all sexually transmitted
infections were provided with a 5-day course of topical metronidazole
(0.75%). Within 48 hours of completing metronidazole treatment,
participants returned to the clinic to evaluate eligibility. Vaginal swabs
were collected at the baseline visit and at the clinic visit immediately after treatment (24–48 hours after completing treatment), before
administration of any study product or placebo. Immediately after
collection, vaginal swabs were plunged into 2 mL of Starplex transport
medium and frozen at –20°C or –80°C.
Soluble immune factor measurement. Cervicovaginal fluid obtained
from vaginal swabs was thawed and centrifuged at 2500g for 30
minutes. Supernatant was then removed for immune factor analysis,
and the bacterial pellet was left intact for qPCR analyses. The solu-

ble immune factors IL-1α, IFN-α2A, IL-17A, IL-6, IP-10, IL-8, MIP1β, MIP-3α, MIG, soluble E-cadherin, and MMP-9 were measured
in duplicate on the MSD platform according to the manufacturer’s
instructions as previously described (Meso Scale Discovery; ref. 24).
DNA extraction and metagenomic sequencing. Samples were plated
from swab collection tubes into ZymoBIOMICS lysis solution for DNA
extraction. DNA was extracted and processed with high-throughput
automation liquid handlers (Agilent Bravo system and Labcyte ECHO
instrument) to maintain constancy in sample experimentation and
decrease laboratory processing time. The ZymoBIOMICS 96 MagBead DNA kit was followed as instructed to extract DNA from swab
samples, water controls, and storage medium controls. Illumina
library preparation was performed using a miniaturized protocol of
NEBNext Ultra II FS DNA Library Prep kit for DNA for the Labcyte
ECHO instrument (25). More than 25 million paired-end 150 bp reads
per patient sample were collected on an Illumina NovaSeq instrument.
The IDSeq bioinformatic pipeline was used to process raw sequencing
reads, removing host reads and aligning with established databases
to identify microbes (26). On average, approximately 1% of collected reads mapped to microbial sequences. Samples with more than
100,000 reads were included in the present analyses.
DNA extraction and qPCR. DNA was extracted from 175 μL of
bacterial pellet from vaginal swab samples using the Qiagen DNeasy
PowerSoil kit according to the manufacturer’s instructions. Targeted qPCR was used to estimate absolute abundances of key bacterial
species, including the 4 most common vaginal Lactobacillus spp. (L.
crispatus, L. iners, L. jensenii, and L. gasseri) and 4 common BV-associated bacterial taxa (G. vaginalis, A. vaginae, Megasphaera spp., and
Prevotella spp.). All qPCR assays were TaqMan-based and performed
on the QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher
Scientific). The protocol for quantification of L. crispatus, L. iners, L.
jensenii, and L. gasseri absolute abundances with multiplex qPCR was
adopted from Balashov and colleagues (27). Absolute abundances of
G. vaginalis, A. vaginae, and Megasphaera spp. were quantified with
multiplex qPCR following Kusters and colleagues (28). Total Prevotella
absolute abundance was quantified with qPCR adopted from Martin
and colleagues (29). Primer and probe sequences are presented in
Supplemental Table 10. Total reaction volume for assays was 10 μL.
Assays for total Prevotella, L. crispatus, L. iners, L. jensenii, and L. gasseri were performed at 95°C for 10 minutes, 45 cycles at 95°C for 15
seconds, and then 60°C for 1 minute. Assays for G. vaginalis, A. vagi-
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nae, and Megasphaera spp. were performed at 95°C for 10 minutes, 45
cycles at 95°C for 15 seconds, and then 55°C for 1 minute. Data analysis was performed with QuantStudio Real-Time PCR Software version
1.3 (Applied Biosystems). To validate the performance of the multiplex
qPCR assays, single-plex qPCR assays were performed for key vaginal bacterial species with standard curves (L. crispatus, L. iners, and G.
vaginalis). Single-plex assays were performed using the same methods
as the multiplex assays, except primers and probes for other bacterial
taxa were replaced with DNase/RNase-free distilled water. For generation of standard curves, L. crispatus (ATCC, 33820) was grown in
chopped meat media (Anaerobic Systems) anaerobically (80% N2;
10% CO2; 10 H2) 37°C; L. iners (ATCC, 55195) and G. vaginalis (ATCC,
14019) were grown in New York City III media aerobically at 37°C and
anaerobically at 37°C, respectively. Copy numbers were quantified
using equation 1, where ΔCt represents the difference in Ct between a
sample and negative control: Copy number = 2ΔCt.
Statistics. Soluble immune factor levels were normalized through
log10 transformation. Paired comparisons of soluble immune factors
between baseline and follow-up were evaluated with Wilcoxon’s
matched-pairs signed-rank test. Soluble immune factors that were
detectable in fewer than half of the samples were analyzed as detectable or undetectable. The change in the proportion of samples with
detectable soluble immune factors was evaluated with McNemar’s
test. The relative abundance of bacteria taxa was calculated from
metagenomic sequencing results as a proportion of taxa reads to total
bacteria reads. CSTs were assigned using taxa relative abundances as
previously described (2). Paired 2-tailed t tests were performed to generate the mean and 95% CI of the change in the relative and absolute
abundance of key bacteria taxa from baseline to follow-up, and P values were calculated with Wilcoxon’s matched-pairs signed-rank test.
Changes in the relative and absolute abundance of key bacteria taxa
were visualized using the “forestplot” package in RStudio (version
1.2.1335). Linear mixed model analysis was performed with SPSS (version 27.0.0.0). All paired comparisons were performed with GraphPad
Prism (version 9.0.2). A P value of 0.05 was considered significant
unless otherwise specified.
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